Evidence map›Paper›PMID 41686352›Full record

ArticleGlycoconjugate journal2026

Salmon proteoglycan modulates TIMP-gelatinase regulation in intestinal epithelial cells.

Shintaro Hirasawa, Tomio Yabe

Abstract read
In one paragraph

Article in Glycoconjugate journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shintaro HirasawaThe United Graduate School of Agricultural Science, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan.
Tomio YabeThe United Graduate School of Agricultural Science, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan. yabe.tomio.r9@f.gifu-u.ac.jp.ORCID 0000-0002-9295-8560

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chondroitin sulfate (CS) and CS proteoglycans (CSPGs) are increasingly used in nutritional and biomedical applications. Although their functional benefits have traditionally been attributed to their translocation into the bloodstream after oral administration, their poor bioavailability, due to high molecular weight and strong negative charge, has prompted substantial debate. In this study, we examined the possibility that CS and CSPG act directly on intestinal epithelial cells, thereby providing an alternative explanation for their physiological effects under non-absorptive conditions. Differentiated Caco-2 cells (human enterocyte) were employed as an in vitro model of the intestinal epithelium. Administration of CS and CSPG modulated tissue inhibitor of metalloproteinase gene expression and altered gelatinase activity in the basolateral compartment. While the two glycans shared some overlapping actions, each also exerted distinct effects reflective of their structural features. These findings suggest that CS and CSPG directly modulate epithelial signaling and reshape the basement membrane microenvironment. Overall, this study suggests a mechanism by which CS/CSPG exerts physiological actions in the intestinal tract independent of systemic absorption, providing a new perspective on the functional outcomes of oral administration.

Indexed as

Epithelial CellsGelatinasesIntestinal MucosaProteoglycansTissue Inhibitor of MetalloproteinasesAnimalsCaco-2 CellsChondroitin Sulfate ProteoglycansChondroitin SulfatesEnterocytesHumansSalmonChondroitin Sulfate ProteoglycansChondroitin SulfatesGelatinasesProteoglycansTissue Inhibitor of MetalloproteinasesChondroitin sulfateIntestinal epitheliumProteoglycanTissue inhibitor of metalloproteinase

Identifiers

PMID41686352
PMCPMC12904971

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.